Octogenarian patients with colorectal cancer: Characterizing an emerging clinical entity

Table 3 Treatment¹

	Study cohort	Older (age ≥ 80 yr)	Younger (age < 80 yr)	P value
No. of LN dissected, mean (SD)2	14.4 (6.1)	14.3 (5.4)	14.4 (6.8)	0.893
Adjuvant/neoadjuvant Tx2	119/271 (43.9)	38/138 (27.5)	81/133 (60.9)	< 0.0001
Oxaliplatin-based adjuvant chemotherapy2	58/116 (50)	11/37 (29.7)	47 (59.5)	0.002
No. of chemotherapy lines in stage IV3
0	12 (20)	9 (34.6)	3 (8.8)	0.016
1	24 (40)	11 (42.3)	13 (38.2)
≥ 2	24 (40)	6 (23.1)	18 (53)
Type of chemotherapy in stage IV, 1st line34				0.239
Fluoropyrimidine	11 (21.6)	6 (30)	5 (16.1)
Fluoropyrimidine+oxaliplatin/irinotecan	40 (78.4)	14 (70)	26 (80.9)
Local interventions to metastatic sites5				< 0.001
None	45 (57)	28 (90.3)	17 (35.4)
Surgery ± other local intervention	31 (39.2)	2 (6.5)	29 (60.4)
Other local intervention	3 (3.8)	1 (3.2)	2 (4.2)
Hematological toxicity, grade ≥ 3	17 (11)	4 (8)	13 (12.5)	0.404
Non-hematological toxicity, grade ≥ 3	37 (23.6)	9 (18)	28 (26.7)	0.261

¹Valid percentages. Missing data as follows: adjuvant/neoadjuvant treatment (n = 4); no. of lymph nodes dissected (n = 20); type of chemotherapy (n = 7); No. of chemotherapy lines (n = 12); local intervention to a metastatic site (n = 4), hematological toxicity (n = 19); non-hematological toxicity (n = 19);

²Data regarding patients who presented with non-metastatic disease;

³Data regarding patients who presented with metastatic disease;

⁴Chemotherapy was given with or without a biological agent including bevacizumab, cetuximab or panitumumab;

⁵Local intervention to a metastatic site included: radiofrequency ablation, chemoembolization, intra-arterial chemotherapy, stereotactic body irradiation, and radiotherapy. LN: Lymph nodes; Tx: Treatment.